Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 4;11:1187. doi: 10.1038/s41467-020-15030-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 8 — Peripheral blood mononuclear cells (PBMCs) were treated with 5 μg per ml of FimH and 2 μg per ml of LPS for 24 h. a The distinctness of the PBDCs from the PBMCs is shown. The lineage markers included CD3, CD14, CD16, CD19, CD20, and CD56. b The expression levels of costimulatory molecules and MHC classes I and II in BDCA1⁺ (upper panel) and BDCA3⁺ DCs (lower panel) are shown. (n = 4 donors, one-way ANOVA, mean ± SEM). c Syngeneic CD4 T cell proliferation and IFN-γ production were measured after co-cultured with stimulated BDCA1⁺ DCs and T cells. d PBMCs were pre-treated with 20 μM MD2 inhibitors for 30 min and subsequently treated with FimH and LPS. The expression of costimulatory molecules and MHC class I and II in BDCA1⁺ (upper panel) and BDCA3⁺ DCs (lower panel) are shown. (n = 4 donors, one-way ANOVA, mean ± SEM).